MAPT and Alzheimer disease: A later study demonstrated a similar effect of other DPP4 inhibitors, saxagliptin and vildagliptin, in which the DPP4i-treatment of an STZ-induced rat model of AD led to a decrease in Aβ, t-tau, p-tau levels, and neuroinflammation, with an improvement in hippocampal memory retention [121,122].